Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

HIV–1 neutralizing antibodies: How full is the bottle?

Nature Medicine volume 5, pages 142–144 (1999)Cite this article

Abstract

Potent neutralizing antibodies protect monkeys from SHIV challenge, but will vaccines ever be able to elicit antibody responses this powerful? (pages 204–216)

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Emini, E.A. et al. Prevention of HIV–1 infection in chimpanzees by gp120 V3 domain–specific monoclonal antibody. Nature 355, 728–730 (1992).

    Article  CAS  Google Scholar 

  2. Burton, D.R. & Moore, J.P. Why do we not have an HIV vaccine and how can we make one? Nature Med. 4, 495–498 (1998).

    Article  CAS  Google Scholar 

  3. Letvin, N.L. Progress in the development of an HIV–1 vaccine. Science 280, 1875–1880 (1998).

    Article  CAS  Google Scholar 

  4. Igarashi, T. et al. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell–free virions from blood plasma. Nature Med. 5, 211–216 (1999).

    Article  CAS  Google Scholar 

  5. Shibata, R. et al. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys. Nature Med. 5, 204– 210 (1999).

    Article  CAS  Google Scholar 

  6. Shibata, R. et al. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1. J. Virol. 70, 4361– 4369 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Montefiori, D.C. et al. Neutralizing and infection enhancing antibody responses to human immunodeficiency virus type 1 in long–term non–progressors. J. Infect. Dis. 173, 60– 67 (1996).

    Article  CAS  Google Scholar 

  8. Montefiori, D.C. et al. Neutralizing antibodies in sera from macaques infected with chimeric simian–human immunodeficiency virus containing the envelope glycoproteins of either a laboratory–adapted variant or a primary isolate of human immunodeficiency virus type 1. J. Virol. 72, 3427–3431 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Zhang, L. et al. Rapid clearance of simian immunodeficiency virus particles from plasma of Rhesus macaques. J. Virol. 73, 855–860 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Sattentau, Q.J. & Moore, J.P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the glycoprotein gp120 oligomer. J. Exp. Med. 182, 185– 196 (1995).

    Article  CAS  Google Scholar 

  11. Zolla–Pazner, S. et al. Neutralization of syncytium–inducing primary isolates by sera from human immunodeficiency virus (HIV)–uninfected recipients of candidate HIV vaccines. J. Infect. Dis. 178, 1502–1506 (1998).

    Article  Google Scholar 

  12. Gauduin, M.–C. et al. Passive immunization with a human monoclonal antibody protects hu–PBL–SCID mice against challenge by primary isolates of HIV–1. Nature Med. 3, 1389–1393 (1997).

    Article  CAS  Google Scholar 

  13. Zhou, J.Y. & Montefiori, D.C. Antibody–mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J. Virol. 71, 2512–2517 (1997).

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Trkola, A. et al. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4–based reagents is independent of coreceptor usage. J. Virol. 72, 1876– 1885 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Belshe, R.B. et al. Induction of immune responses to HIV–1 by canarypox virus (ALVAC) HIV–1 and gp120 SF–2 recombinant vaccines in uninfected volunteers. AIDS 12, 2407– 2415 (1998).

    Article  CAS  Google Scholar 

  16. Connor, R.I. et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72, 1552–1576 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Polacino, P. et al. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J.Virol. 73, 618– 630 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Aaron Diamond AIDS Research Center, New York, 10016, New York, USA

    John P. Moore

  2. Depts. of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, 92037, California, USA

    Dennis R. Burton

Authors
  1. John P. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dennis R. Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moore, J., Burton, D. HIV–1 neutralizing antibodies: How full is the bottle?. Nat Med 5, 142–144 (1999). https://doi.org/10.1038/5502

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/5502

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing